Absynth Biologics Limited

Biosynexus, Inc.

University of Sheffield

Absynth Biologics Limted

Simon J Foster

Jorge Garcia-Lara

Philip McDowell

Jorge Garcia Lara

Simon Clarke

Kirsty Brummell

Gerald Walter Fischer

James J Mond

Richard F Schuman

Jeffrey R Stinson

John Fitzgerald Kokai-Kun

Kristy Brummel

The disclosure relates to a composition comprising one, two or more immunogenic bacterial polypeptides and multivalent and monovalent vaccine compositions comprising the immunogenic bacterial polypeptides.

Bacterial vaccine

The disclosure relates to a composition comprising two or more immunogenic staphylococcal polypeptides and a multivalent vaccine composition comprising the immunogenic staphylococcal polypeptides.

Combination vaccine

The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.

[object Object]

The invention relates to an antigenic polypeptide referred to as DivlB and variants thereof, vaccines comprising said polypeptide and the use of the vaccine in protecting subjects from microbial infection.

The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising the polypeptides; recombinant methods to manufacture the polypeptides; and therapeutic antibodies directed to the polypeptides.

The present invention relates to antigenic polypeptides expressed by pathogenic microbes, including antigenic polypeptides encoded by the nucleic acid sequence of FIG., vaccines comprising the antigenic polypeptides and therapeutic antibodies directed to the antigenic polypeptides.

The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising such polypeptides; recombinant methods to manufacture such polypeptides; and therapeutic antibodies directed to such polypeptides.

Staphylococcus aureus antigenic polypeptides and compositions

A method for the identification of antigenic polypeptides, typically opsonic antigens, expressed by pathogenic microbes; vaccines comprising said antigens; and therapeutic antibodies directed to said antigenic polypeptides.

Antigenic polypeptides

The present invention encompasses protective monoclonal antibodies that bind to peptidoglycan of Gram-positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and block nasal colonization by Gram-positive bacteria in vivo. The invention also provides human, humanized and chimeric antibodies. The invention also sets forth the heavy chain and light chain variable regions of an antibody within the invention.

Growing community of inventors

Sheffield, United Kingdom

Simon J Foster